Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1614 1615 1621 1627 1672
This examiner grants 85% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18285439 | IMMUNOFUNCTIONAL CARRIER, METHODS OF USES, AND COMPOSITION MATTERS AS AN ANTITUMOR IMMUNOTHERAPY | Final Rejection | Purdue Research Foundation |
| 18562616 | NUCLEIC ACID-CONJUGATED POLYMERIC NANOPARTICLES AND METHODS OF USE | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18489240 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | Final Rejection | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18021637 | INJECTABLE HYDROGELS AND METHODS OF CAPTURING CELLS USING THE SAME | Final Rejection | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. |
| 18292746 | COSMETIC TREATMENT METHOD COMPRISING THE APPLICATION OF A COMPOSITION COMPRISING AT LEAST ONE ANTIOXIDANT AND A BIFIDOBACTERIUM SPECIES LYSATE | Non-Final OA | L'Oreal |
| 18570477 | 2-[3-[1 [(QUINAZOLIN-4-YL)AMINO]ETHYL]PYRAZIN-2-YL]THIAZOLE-5-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS PESTICIDES | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18696420 | POLYMERIC MICELLE NANOPARTICLES FOR ON-DEMAND CELLULAR PACKAGING OF EXTRACELLULAR VESICLES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18237151 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | Final Rejection | L.E.A.F. HOLDINGS GROUP LLC |
| 18831041 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
| 18153896 | BI-1 ANTAGONISTS AND THEIR USES | Non-Final OA | INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITY |
| 18603433 | Engineered Exosome for Treating Hypertrophic Scar (Hts), and Preparation Method and Use Thereof | Final Rejection | CHINESE PLA GENERAL HOSPITAL |
| 18593290 | Mechanism for Bioavailable Delivery of Electrolytes | Non-Final OA | Inlyte LLC |
| 18683745 | MODIFIED COLLOIDAL PARTICLES FOR USE IN THE TREATMENT OF HAEMOPHILIA A | Non-Final OA | Cantab Biopharmaceuticals Patents Limited |
| 18418727 | SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID | Non-Final OA | MOCHIDA PHARMACEUTICAL CO., LTD. |
| 17920116 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER | Final Rejection | UNIVERSITÉ CATHOLIQUE DE LOUVAIN |
| 18578830 | A GLUCOSE-SENSITIVE INSULIN-LOADED MICROPARTICLE | Non-Final OA | IRCCS "OSPEDALE POLICLINICO SAN MARTINO" |
| 17838891 | SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY | Non-Final OA | Trustees of Tufts College |
| 18568199 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | Non-Final OA | Precious Future (Guangdong) Biotechnologies Ltd. |
| 18288322 | NON-CERULOPLASMIN BOUND COPPER LEVEL MONITORING | Non-Final OA | ORPHALAN S.A. |
| 18554382 | WNT AGONISTS FOR PREVENTION OF CANCER | Non-Final OA | ACADEMISH MEDISCH CENTRUM |
| 18042743 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | Non-Final OA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN |
| 18044269 | FLOCCULANT BASED DISINFECTION PROCESS FOR PATHOGENIC MEDICAL WASTE DISPOSAL | Non-Final OA | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH |
| 17996734 | USE OF IRAK4 INHIBITOR IN TREATMENT OF ACUTE LUNG INJURY ALI/ARDS | Non-Final OA | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
| 17917658 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Non-Final OA | AVENTI INC. |
| 16858244 | QUINOLINE DERIVATIVE | Non-Final OA | ONO PHARMACEUTICAL CO., LTD. |
| 17621948 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DILTIAZEM | Non-Final OA | S.L.A. Pharmca AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy